News and Press Releases
Scientific publication: Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in PeptiCRAd cancer vaccine platform
ValoTx is pleased to share a new publication in Molecular Therapy Oncolytics (2021 in press) from IVTLab and Valo Therapeutics on PeptiCRAd technology and our proprietary oncolytic adenovirus platform. A link to the paper can be found here Abstract Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules including various cytokines or chemokines. Here, we have developed
Valo Therapeutics Granted USA Patent for PeptiCRAd Technology in Cancer Immunotherapy
Helsinki, 24th November, 2020 Valo Therapeutics, the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced that the US Patent Office has granted US Patent No 10,799,568 on 13 October 2020, covering its lead PeptiCRAd platform technology. The patent covers the use of adenoviral vectors having tumor-specific peptides attached to the viral capsid, for stimulating targeted anti-tumor immune responses in cancer patients. Patents for PeptiCRAd technology have been previously granted in Europe (No 3145537) and in
This Startup is Making a Cancer Vaccine out of Viruses
Valo Therapeutics is operating both in the UK and Finland to develop a cancer vaccine based on a virus designed to kill tumors.
Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce that Russell LaMontagne of Boston Immune Technologies and Therapeutics was chosen as the winner of the Lyfebulb-Helsinn Innovation Award, and Cesare Spadoni, PhD, of Oncoheroes Biosciences was chosen as the winner of the Squinto-LePera Award by
BioCentury Innovations Emerging Company Profile - "Valo: adding tumor antigens to oncolytic viruses"
BioCentury Innovations Emerging Company Profile "ValoTx: adding tumor antigens to oncolytic viruses" "With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immunooncology companies..." Read full article here: https://drive.google.com/file/d/1Ye_k2h4nUh9R5FxxpAlIqiH9ko5_xQtr/view?usp=sharing